Letters to the Editor

Efficacy of combined low-dose ruxolitinib and cyclosporine in murine immune bone marrow failure

Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD
Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD
Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD
Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD
Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD
Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD
Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD
Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD
Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD
Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD
Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD
Vol. 109 No. 5 (2024): May, 2024 https://doi.org/10.3324/haematol.2023.284358